Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

SPERO THERAPEUTICS, INC.

(SPRO)
  Report
Delayed Nasdaq  -  04:00:00 2023-01-26 pm EST
1.850 USD   +0.54%
01/09Spero Therapeutics, Inc. : Results of Operations and Financial Condition, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits (form 8-K)
AQ
2022Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
2022Spero Therapeutics, Inc.(NasdaqGS:SPRO) dropped from NASDAQ Biotechnology Index
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Sector Update: Health Care Stocks Mixed Premarket Thursday

09/22/2022 | 09:25am EST


ę MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
DBV TECHNOLOGIES -2.53% 2.618 Real-time Quote.-14.62%
GSK PLC 0.11% 1405.2 Delayed Quote.-2.37%
NOVARTIS AG -3.07% 82.68 Delayed Quote.2.05%
SPERO THERAPEUTICS, INC. 0.54% 1.85 Delayed Quote.6.36%
All news about SPERO THERAPEUTICS, INC.
01/09Spero Therapeutics, Inc. : Results of Operations and Financial Condition, Regulation FD Di..
AQ
2022Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
2022Spero Therapeutics, Inc.(NasdaqGS:SPRO) dropped from N..
CI
2022Spero Therapeutics to Present at the 5th Annual Evercore ISI HealthCONx Conference
AQ
2022Transcript : Spero Therapeutics, Inc., Q3 2022 Earnings Call, Nov 14, 2022
CI
2022Earnings Flash (SPRO) SPERO THERAPEUTICS Posts Q3 Revenue $2M
MT
2022SPERO THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition a..
AQ
2022Spero Therapeutics Announces Third Quarter 2022 Operating Results and Provides Business..
AQ
2022Spero Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months..
CI
2022Spero Therapeutics Closes License Deal With GSK for Investigational Drug for Urinary Tr..
MT
More news
Analyst Recommendations on SPERO THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2022 39,6 M - -
Net income 2022 -70,4 M - -
Net Debt 2022 - - -
P/E ratio 2022 -0,87x
Yield 2022 -
Capitalization 95,8 M 95,8 M -
Capi. / Sales 2022 2,42x
Capi. / Sales 2023 3,50x
Nbr of Employees 41
Free-Float 76,6%
Chart SPERO THERAPEUTICS, INC.
Duration : Period :
Spero Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SPERO THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 1,85 $
Average target price 6,33 $
Spread / Average Target 242%
EPS Revisions
Managers and Directors
Ankit A. Mahadevia President, Chief Executive Officer & Director
Satyavrat Shukla Chief Financial Officer & Treasurer
Milind S. Deshpande Chairman
Thomas R. Parr Chief Scientific Officer
Angela Talley Vice President-Clinical Development
Sector and Competitors
1st jan.Capi. (M$)
SPERO THERAPEUTICS, INC.6.36%95
VERTEX PHARMACEUTICALS8.58%80 930
REGENERON PHARMACEUTICALS, INC.0.83%79 159
WUXI APPTEC CO., LTD.20.37%42 279
BIONTECH SE-4.99%34 686
BEIGENE, LTD.19.81%27 392